// App-Quantinova.ai

1441 : Safety and Antitumor Effects of CD19-Specific Autologous Chimeric Antigen Receptor-Modified T (CAR-T) Cells Expressing the Inducible Caspase 9 Safety Switch (iC9-CAR19 T Cells) in Adult Acute Lymphoblastic Leukemia (ALL)

Researchers

Presenter

  • Matthew C Foster

Principal Investigators

  • Philip A. Roehrs

  • George E Hucks

  • Natalie S Grover

  • Paul M. Armistead

  • Katarzyna Jamieson

  • Faith Brianne Buchanan

  • J. Kaitlin C Morrison

  • Spencer Laing

  • Catherine Joyce Arago Cheng

  • Jonathan S. Serody

  • Gianpietro Dotti

  • Barbara Savoldo

Medical Centers

  • Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, Chapel Hill, NC

  • Carolinas Medical Center, Charlotte, NC

  • Division of Pediatric Hematology/Oncology and Bone Marrow Transplant, University of North Carolina, Chapel Hill, NC

  • Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC

  • Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved